Through B-cell lymphoma 2 (Bcl-2) homology domain 3 (BH3) profiling, we found that these resistant cells were dependent on Bcl-2 for survival and combined treatment using dexamethasone, FLT3/SFK inhibition by RK-20449 and Bcl-2 inhibition by ABT-199 completely eradicated human MLL-ALL cells both in vitro and in vivo. Here, BCL2 is linked to acute lymphoblastic leukemia.